Psychedelics

Alaska Airlines pilot who tried to cut engines told police he thought he was dreaming – Court documents show he’d taken psychedelic mushrooms “recently”

Published

7 months ago

October 25, 2023

admin

Probably not the best idea to let pilots do self administered psilocybin therapy!

The Guardian reports

An off-duty Alaska Airlines pilot who tried to cut the engines on a regional jet mid-flight on Sunday told police after his arrest that he believed he was having a nervous breakdown, thought he was dreaming when he pulled fire handles in the cockpit, and that he had experimented with psychedelic mushrooms recently as his mental health worsened, according to a federal complaint made public on Tuesday.

Just before trying to cut the engines, Joseph David Emerson, 44, who was riding in an extra seat in the cockpit said: “I’m not OK” and later told police he had recently taken psychedelic mushrooms, according to charging documents.

State prosecutors in Oregon filed 83 counts of attempted murder against Emerson on Tuesday just before he appeared in court, with his attorney, Noah Horst, entering not guilty pleas on his behalf. Federal prosecutors meanwhile charged Emerson with interfering with a flight crew, which can carry up to 20 years in prison.

Emerson, of Pleasant Hill, California, was initially arrested in Oregon on Sunday night on state counts of attempted murder after the flight crew reported his attempt to shut down the engines on a flight from Washington state to California. The plane was diverted to Portland, where it landed safely with more than 80 people onboard.

Emerson, who as an off-duty pilot was authorized to ride in the cockpit’s jump seat, made casual conversation with the captain and first officer when the plane was between Astoria, Oregon, and Portland, before trying to grab two red handles that would have activated the plane’s fire-suppression system and cut off fuel to its engines, according to the federal complaint.

After what the flight crew described as a brief struggle, lasting only about 30 seconds, Emerson left the cockpit, the FBI said.

Flight attendants placed Emerson in wrist restraints and seated him in the rear of the aircraft, but as the plane descended, he tried to grab the handle of an emergency exit, according to the document. A flight attendant stopped him by placing her hands on top of his, it said.

The Associated Press has been unable to contact Emerson’s family or others who might speak on his behalf.

According to a probable cause statement filed in Multnomah county circuit court, Emerson told Port of Portland police following his arrest that he had been struggling with depression, that a friend had recently died and that he had taken psychedelic mushrooms about 48 hours before he attempted to cut the engines. He also said he had not slept in more than 40 hours, according to the document.

Police reported that Emerson did not appear to be intoxicated at the time of the interview, and in a statement Tuesday, Alaska Airlines said neither the gate agents nor the flight crew noticed any signs of impairment that might have barred him from the flight. An FBI agent wrote in a probable cause affidavit in support of the federal charge that Emerson “said it was his first-time taking mushrooms”.

The captain and first officer told police that after Emerson said: “I’m not OK” he reached up to pull the handles, and they were able to stop him before he pulled the handles all the way down, the affidavit said.

Emerson walked calmly to the back of the plane after being told to leave the cockpit and told a flight attendant: “You need to cuff me right now or it’s going to be bad,” according to the affidavit. Another flight attendant heard him saying: “I messed everything up” and “tried to kill everybody”.

According to the affidavit, Emerson asked police whether he could waive his right to an attorney: “I’m admitting to what I did. I’m not fighting any charges you want to bring against me, guys.”

He also told them: “I pulled both emergency shut-off handles because I thought I was dreaming and I just wanna wake up,.”

https://www.theguardian.com/us-news/2023/oct/24/alaska-airlines-diverted-pilot-engines-psychedelic-mushrooms

Source link

Psychedelics

Press Release: PsychedelicNewsWire Named Official Media Sponsor of the 4th Annual Psychedelic Therapeutics and Drug Development Conference

Published

15 hours ago

May 18, 2024

admin

LOS ANGELES, May 17, 2024 (GLOBE NEWSWIRE) — PsychedelicNewsWire (“PNW”), a specialized communications platform for the psychedelics sector and one of the 60+ brands powered by IBN (“InvestorBrandNetwork”), is pleased to announce that it will be the Official Media Sponsor for the 4^th Annual Psychedelic Therapeutics and Drug Development Conference (“the conference”), an industry flagship event dedicated to research and development of psychedelics in the healthcare space hosted by Arrowhead SciTech Conferences & Events (“Arrowhead”). The event will be held at the iconic Revere Hotel Boston Common, 200 Stuart Street, Boston, MA 02116 on 23-24 May 2024

Source link

individualized treatment

Risks of Psychedelics for People with Personality Disorders

Published

1 week ago

May 9, 2024

admin

While psychedelics have shown promise in treating certain mental health conditions, a recent study suggests they may pose risks for individuals with personality disorders. The findings underscore the importance of careful screening and personalized approaches in psychedelic-assisted therapy.

Navigating the Psychedelic Landscape: Potential Risks for Individuals with Personality Disorders

Psychedelics, including substances like psilocybin and LSD, have gained significant traction in recent years for their potential therapeutic benefits in treating mental health conditions such as depression, anxiety, and PTSD. However, a recent publication in the Journal of Psychopharmacology has raised concerns about the suitability of these substances for individuals with personality disorders.

The study surveyed individuals who had used psychedelics and who were also diagnosed with personality disorders. A considerable number of respondents reported negative and persistent psychological impacts following their psychedelic experiences. Notably, these included heightened anxiety, paranoia, mood instability, and an exacerbation of existing personality disorder symptoms.

Researchers suggest that the vulnerability of individuals with personality disorders to the adverse effects of psychedelics may stem from pre-existing challenges in emotional regulation, self-identity, and interpersonal relationships. The profound and introspective nature of psychedelic experiences can intensify these issues, potentially leading to psychological distress and symptom aggravation.

This research highlights the critical need for thorough screening and assessment in the context of psychedelic-assisted therapy. It suggests that individuals with personality disorders might require tailored therapeutic approaches and robust support systems to navigate potential risks and to secure safe and positive outcomes.

Why It Matters

The burgeoning interest in psychedelic therapy underscores the necessity to discern both the potential benefits and risks across different demographic groups. This study contributes valuable insights, particularly for clinicians and researchers, stressing the importance of personalized treatment plans and the cautious consideration of individual vulnerabilities when administering psychedelic-assisted therapy.

Potential Implications

The findings from this study emphasize the need for ethical and responsible practices within the field of psychedelic-assisted therapy. There is a pressing requirement for the development of detailed screening protocols that can identify individuals who may be more susceptible to the adverse effects of psychedelics. Furthermore, crafting specialized therapeutic strategies that cater specifically to the needs of individuals with personality disorders is essential for ensuring their safety and overall well-being during and after undergoing psychedelic experiences.

The Bigger Picture

The debate surrounding the therapeutic use of psychedelics is complex, with various factors influencing the suitability of these treatments for different individuals. While there are promising results in general populations, the nuanced needs and potential vulnerabilities of those with personality disorders require careful consideration to prevent harm and maximize therapeutic outcomes. This necessitates ongoing research, improved clinical protocols, and a commitment to patient-centered care in the burgeoning field of psychedelic medicine.

Source: Science Alert

Source link

antidepressants

Treating Depression: Psychedelics vs. Antidepressants

Published

1 week ago

May 9, 2024

admin

Recent research suggests that psychedelics and traditional antidepressants, while both potentially effective in treating depression, work through distinct mechanisms. Understanding these differences could lead to more personalized and effective treatment approaches. Psychedelics vs. Antidepressants: What are the key differences?

Unlocking the Mysteries of Depression Treatment: Psychedelics vs. Antidepressants

The quest for effective depression treatments continues to be a significant focus in mental health research. Traditional antidepressants, like selective serotonin reuptake inhibitors (SSRIs), have been a mainstay in treatment, prescribed widely despite varying efficacy among individuals and often accompanying unwanted side effects. In contrast, psychedelics have recently garnered attention for their rapid and enduring antidepressant effects observed in clinical trials.

A recent study has delved into the distinct mechanisms of action of SSRIs and psychedelics, illuminating how they uniquely influence the brain and potentially alleviate symptoms of depression. SSRIs primarily increase serotonin levels in the brain, which is believed to enhance mood and diminish depressive symptoms. However, this process can require several weeks to manifest noticeable effects, and not all patients respond favorably to SSRIs.

Conversely, psychedelics such as psilocybin, found in “magic mushrooms,” operate through a different mechanism. Research indicates that psilocybin’s antidepressant effects are not directly due to elevated serotonin levels. Instead, psilocybin is thought to promote neuroplasticity, the brain’s capacity to reorganize and form new neuronal connections. This heightened neuroplasticity may facilitate more adaptable thought patterns and an improved ability to process emotions, contributing to the rapid and sustained antidepressant effects seen in clinical trials.

Moreover, the study examined the role of the 5-HT2A serotonin receptor, a primary target for both SSRIs and psychedelics. While SSRIs inhibit this receptor’s activity, psychedelics activate it. Intriguingly, blocking the 5-HT2A receptor did not reduce psilocybin’s antidepressant effects, suggesting that its therapeutic benefits originate from other pathways.

Psychedelics vs. Antidepressants: Why It Matters?

Understanding the distinct mechanisms by which psychedelics and antidepressants affect the brain is crucial for the development of more personalized and effective treatment strategies for depression. This knowledge could lead to enhanced patient selection for specific treatments, reducing trial and error while optimizing outcomes. Furthermore, exploring the unique properties of psychedelics may pave the way for novel antidepressant medications that are quicker acting and have fewer side effects.

Potential Implications

This research could catalyze a shift in depression treatment paradigms, moving from a one-size-fits-all approach to more targeted therapies. By pinpointing the specific mechanisms that underlie different antidepressant interventions, clinicians can customize treatment plans based on individual patient profiles and needs. This personalized approach could improve treatment success rates and enhance the quality of life for individuals battling depression.

What Next?

While the study of psychedelics for therapeutic purposes is still in its nascent stages, the initial findings are promising and suggest that psychedelics may offer a valuable addition to the arsenal of tools for combating depression and other mental health conditions.

Source: Neuroscience News

Source link